Large gap with delayed quotes
|
Last quote
04/27/2026
-
19:11:49
|
Bid
04/27/2026 -
19:14:02
|
Bid Volume |
Ask
04/27/2026 -
19:14:02
|
Ask Volume |
|---|---|---|---|---|
|
20.59
+0.29
(
+1.43% )
|
20.60
|
100 |
20.61
|
100 |
Analysis date: 24.04.2026
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 21.04.2026.
Interest
Very strong
Very strong
Four stars since 21.04.2026.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 21.04.2026 at a price of 20.68.
Evaluation
Neutral
Neutral
Based on its growth potential and our own criteria, we believe the share price is currently fairly priced.
MT Tech Trend
Neutral
Neutral
The stock is currently trading close to its dividend-adjusted forty day moving average (changes between +1.75% and -1.75% are considered neutral). Prior to this, the stock traded above its moving average since 27.03.2026.
4wk Rel Perf
5.99%
5.99%
The four-week dividend-adjusted overperformance versus SP500 is 5.99%.
Sensibility
High
High
High, no change over 1 year.
Bear Market Factor
High
High
On average, the stock has a tendency to amplify the drops in the index by 0.99%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 8.75%.
Mkt Cap in $bn
2.13
2.13
With a market capitalization between $2 & $8bn, SAREPTA THERAPEUTICS is considered a mid-cap stock.
G/PE Ratio
0.73
0.73
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) below 0.9 indicates that investors must pay a premium for the estimated growth potential:
LT P/E
24.45
24.45
The estimated PE is for the year 2028.
LT Growth
17.86%
17.86%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
18
18
Over the last seven weeks, an average of 18 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
81
81
For 1% of index variation, the stock varies on average by 0.81%.
Correlation
0.13
0.13
Stock movements are totally independent of index variations.
Value at Risk
10.54
10.54
The value at risk is estimated at USD 10.54. The risk is therefore 51.90%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
21.05.2013
21.05.2013